Trial Profile
A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Pfizer
- 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2010 Actual patient number (65) added as reported by ClinicalTrials.gov.
- 17 Nov 2009 Planned end date changed from 1 Jan 2010 to 1 Dec 2009 as reported by ClinicalTrials.gov.